Back to top
more

Orthofix Medical (OFIX)

(Delayed Data from NSDQ)

$17.71 USD

17.71
294,743

+0.38 (2.19%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $17.70 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Wall Street Analysts Believe Orthofix (OFIX) Could Rally 47%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 46.7% upside potential for Orthofix (OFIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Orthofix (OFIX) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 107.69% and 0.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of -23.08% and -0.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Orthofix (OFIX) Reaches Milestone for M6-C Disc Implants

by Zacks Equity Research

Orthofix (OFIX) reveals that more than 60,000 M6-C artificial cervical discs have been implanted worldwide.

Trina Mukherjee headshot

3 Promising MedTech Stocks to Snap Up in Second-Half 2021

by Trina Mukherjee

Backed by robust long-term prospects, investors can add three lucrative MedTech stocks, MMSI, ITGR and OFIX, to their watchlist.

Debanjana Dey headshot

5 Stocks to Deflect Delta Variant Curveball From Orthopedic Space

by Debanjana Dey

OrthoPediatrics (KIDS), Orthofix (OFIX), Zimmer Biomet (ZBH), Stryker (SYK) and SeaSpine (SPNE) are expected to hold ground despite a challenging business climate.

Orthofix (OFIX) Fitbone Used in 1st US Pediatric Patient Implant

by Zacks Equity Research

Orthofix's (OFIX) Fitbone system is the only intramedullary limb lengthening solution to get FDA clearance for pediatric and adult use.

Orthofix (OFIX) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 100.00% and 11.01%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Orthofix's (OFIX) SpinalStim Demonstrates Improved Fusion Rates

by Zacks Equity Research

Orthofix's (OFIX) SpinalStim bone growth device demonstrates impressive fusion rates for patients recovering from lumbar fusion surgery.

Orthofix (OFIX) Launches FORZA Ti PLIF Spacer System in the US

by Zacks Equity Research

Orthofix (OFIX) launches FORZA Ti PLIF Spacer System to improve posterior lumbar interbody fusion procedures in the United States.

Orthofix (OFIX) Launches OSCAR PRO System in the US & Europe

by Zacks Equity Research

Orthofix's (OFIX) latest innovation is expected to drive organic growth in its Global Orthopedics business.

Orthofix's (OFIX) Q1 Earnings Top Estimates, 2021 View Up

by Zacks Equity Research

Strong sales of Orthofix's (OFIX) M6-C artificial disc and FITBONE lengthening nail drive its Q1 top line.

Orthofix (OFIX) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 142.86% and 10.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Orthopedic Space Gains Momentum in 2021: 5 Stocks in Focus

by Debanjana Dey

Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.

Orthofix (OFIX) Wins FDA Clearance for CONSTRUX Mini Ti System

by Zacks Equity Research

Orthofix's (OFIX) CONSTRUX Mini Ti Spacer System, designed with nanoscale surface is the first 3D-printed titanium interbody, was launched to enhance ACDF procedures.

Orthofix's (OFIX) Q4 Earnings Top Estimates, Margin Declines

by Zacks Equity Research

Orthofix (OFIX) registers improvement in Global Spine segment's revenues during Q4 due to strength in its spinal implants portfolio.

Orthofix (OFIX) Launches Limb Lengthening System in US & UK

by Zacks Equity Research

With FITBONE, Orthofix (OFIX) claims itself to be the only orthopedic company that offers a comprehensive portfolio of both internal and external fixation solutions for limb reconstruction.

Orthofix (OFIX) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 247.62% and 29.28%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in Pharmaceutical segment.

What's in Store for Becton, Dickinson's (BDX) Q4 Earnings?

by Zacks Equity Research

Becton, Dickinson's (BDX) fiscal fourth-quarter results likely to reflect robust performance at BD Life Sciences.

Orthofix (OFIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Orthofix (OFIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Orthofix (OFIX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 26.25% and 35.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?